Literature DB >> 19181654

Pulmonary hypertension: diagnosis and management.

Michael D McGoon1, Garvan C Kane.   

Abstract

Pulmonary arterial hypertension is a progressive, symptomatic, and ultimately fatal disorder for which substantial advances in treatment have been made during the past decade. Effective management requires timely recognition and accurate diagnosis of the disorder and appropriate selection among therapeutic alternatives. Despite progress in treatment, obstacles remain that impede the achievement of optimal outcomes. The current article provides an overview of the pathobiologic mechanisms of pulmonary arterial hypertension, including genetic substrates and molecular and cellular mechanisms, and describes the clinical manifestations and classification of pulmonary arterial hypertension. The article also reviews established approaches to evaluation and treatment, with emphasis on the appropriate application of calcium channel blockers, prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors. In addition, the authors discuss unresolved issues that may complicate patient management, such as the clinical importance of mild or exercise-related pulmonary arterial hypertension, and they identify avenues by which treatment may advance in the future through the use of combination treatment, outcomes assessment, and exploration of alternative pharmacologic strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19181654      PMCID: PMC2664591          DOI: 10.1016/S0025-6196(11)60828-8

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  98 in total

1.  Extrinsic compression of the left main coronary artery by the pulmonary artery in patients with long-standing pulmonary hypertension.

Authors:  S M Kawut; F E Silvestry; V A Ferrari; D DeNofrio; L Axel; E Loh; H I Palevsky
Journal:  Am J Cardiol       Date:  1999-03-15       Impact factor: 2.778

2.  Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.

Authors:  M M Hoeper; C Faulenbach; H Golpon; J Winkler; T Welte; J Niedermeyer
Journal:  Eur Respir J       Date:  2004-12       Impact factor: 16.671

3.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

Authors:  Nazzareno Galiè; Adam Torbicki; Robyn Barst; Philippe Dartevelle; Sheila Haworth; Tim Higenbottam; Horst Olschewski; Andrew Peacock; Giuseppe Pietra; Lewis J Rubin; Gerald Simonneau; Silvia G Priori; Maria Angeles Alonso Garcia; Jean-Jacques Blanc; Andrzej Budaj; Martin Cowie; Verconcia Dean; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; Keith McGregor; João Morais; Ali Oto; Otto A Smiseth; Joan Albert Barbera; Simon Gibbs; Marius Hoeper; Marc Humbert; Robert Naeije; Joanna Pepke-Zaba
Journal:  Eur Heart J       Date:  2004-12       Impact factor: 29.983

4.  Pulmonary hypertension.

Authors:  Paul McLoughlin; Jean-Marc Hyvelin; Katherine Howell
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

5.  Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.

Authors:  V V McLaughlin; D E Genthner; M M Panella; D M Hess; S Rich
Journal:  Ann Intern Med       Date:  1999-05-04       Impact factor: 25.391

6.  Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.

Authors:  E B Rosenzweig; D Kerstein; R J Barst
Journal:  Circulation       Date:  1999-04-13       Impact factor: 29.690

7.  The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

Authors:  S Rich; V V McLaughlin
Journal:  J Am Coll Cardiol       Date:  1999-10       Impact factor: 24.094

8.  Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment.

Authors:  J Sandoval; J Gaspar; T Pulido; E Bautista; M L Martínez-Guerra; M Zeballos; A Palomar; A Gómez
Journal:  J Am Coll Cardiol       Date:  1998-08       Impact factor: 24.094

9.  Plasma coagulation profiles in patients with severe primary pulmonary hypertension.

Authors:  M M Hoeper; M Sosada; H Fabel
Journal:  Eur Respir J       Date:  1998-12       Impact factor: 16.671

10.  Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension.

Authors:  J X Yuan; A M Aldinger; M Juhaszova; J Wang; J V Conte; S P Gaine; J B Orens; L J Rubin
Journal:  Circulation       Date:  1998-10-06       Impact factor: 29.690

View more
  32 in total

1.  Noninvasive pulmonary artery pressure monitoring by EIT: a model-based feasibility study.

Authors:  Martin Proença; Fabian Braun; Josep Solà; Jean-Philippe Thiran; Mathieu Lemay
Journal:  Med Biol Eng Comput       Date:  2016-09-17       Impact factor: 2.602

2.  Survival in an incident cohort of patients with pulmonary arterial hypertension in Denmark.

Authors:  Kasper Korsholm; Asger Andersen; Rikke E Kirkfeldt; Knud N Hansen; Søren Mellemkjær; Jens Erik Nielsen-Kudsk
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

Review 3.  Assessment and treatment of right ventricular failure.

Authors:  Marc A Simon
Journal:  Nat Rev Cardiol       Date:  2013-02-12       Impact factor: 32.419

4.  The Yin and Yang of endothelium-derived vasodilator factors.

Authors:  Andrew O Kadlec; David D Gutterman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-19       Impact factor: 4.733

Review 5.  Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease.

Authors:  Monnipa Suesaowalak; John P Cleary; Anthony C Chang
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

6.  Pulmonary arterial hypertension in the setting of pregnancy: a case series and standard treatment approach.

Authors:  J Shaun Smith; Julianne Mueller; Curt J Daniels
Journal:  Lung       Date:  2011-12-03       Impact factor: 2.584

7.  Contribution of oxidative stress to pulmonary arterial hypertension.

Authors:  Vincent G Demarco; Adam T Whaley-Connell; James R Sowers; Javad Habibi; Kevin C Dellsperger
Journal:  World J Cardiol       Date:  2010-10-26

8.  Arterial-ventricular and interventricular interaction in isolated post-capillary and combined pulmonary hypertension in severe mitral stenosis.

Authors:  Ashwin Venkateshvaran; Srikanth Sola; Satish Chandra Govind; Pravat Kumar Dash; Sagar Vyavahare; Lars H Lund; Bé la Merkely; Anikó Ilona Nagy; Aristomenis Manouras
Journal:  Eur J Appl Physiol       Date:  2016-05-19       Impact factor: 3.078

9.  Stimulators of soluble guanylyl cyclase: future clinical indications.

Authors:  Bobby D Nossaman; Philip J Kadowitz
Journal:  Ochsner J       Date:  2013

10.  Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®.

Authors:  Natalie Kitterman; Abby Poms; Dave P Miller; Sandra Lombardi; Harrison W Farber; Robyn J Barst
Journal:  Mayo Clin Proc       Date:  2012-08-09       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.